Abstract
Background: Elderly patients (65 years and over) develop often, sometimes predominantly , esophageal, gastro esophageal junction, gastric and pancreatic cancer (gastrointestinal non colorectal cancer). Most clinical trials exclude elderly patients from accrual considering aging a potential risk factor. In fact an elderly patient can develop greater toxicity than a younger patient from oncologic treatments (chemotherapy, radiotherapy, target therapies) due to a worse function of vital organs.
Methods: We analyzed the current scientific literature, searching articles since 1990, about gastrointestinal non colorectal cancer in elderly patients, to establish if they need a specific management, different from younger patients.
Results: Data from analyzed studies, both gastro esophageal and pancreatic cancer, are contradictory. In some reports elderly patients don’t seem to bring greater toxicity than younger. Other trials consider that dose-adjustment to renal function is need in elderly patients, but these trials are very few. Other trials may include several biases such as accrual of “only fit” elderly patients.
Conclusions: It is very important in elderly patients with higher risk of toxicity, to distinguish the aim of cancer treatment: is it curative or palliative? Furthermore, in this type of patients the most important target is probably maintaining the quality of life especially in gastric and pancreatic cancer that often started as advanced disease. For these valuation chronological age alone is not sufficient. Another very important factor in elderly cancer patients is the geriatric assessment including not only age but also functional, social and mental status.
Keywords: Elderly, gastric cancer, pancreatic cancer, chemotherapy, target therapy.
Anti-Cancer Agents in Medicinal Chemistry
Title:Gastrointestinal Non Colorectal Cancer. Do Elderly Patients Need a Specific Management?
Volume: 13 Issue: 9
Author(s): Lucrezia Silvestro, Guglielmo Nasti, Alessandro Ottaiano, Massimo Montano, Rossana Casaretti, Antonio Avallone, Massimiliano Berretta, Carmela Romano, Antonio Cassata, Salvatore Tafuto and Rosario Vincenzo Iaffaioli
Affiliation:
Keywords: Elderly, gastric cancer, pancreatic cancer, chemotherapy, target therapy.
Abstract: Background: Elderly patients (65 years and over) develop often, sometimes predominantly , esophageal, gastro esophageal junction, gastric and pancreatic cancer (gastrointestinal non colorectal cancer). Most clinical trials exclude elderly patients from accrual considering aging a potential risk factor. In fact an elderly patient can develop greater toxicity than a younger patient from oncologic treatments (chemotherapy, radiotherapy, target therapies) due to a worse function of vital organs.
Methods: We analyzed the current scientific literature, searching articles since 1990, about gastrointestinal non colorectal cancer in elderly patients, to establish if they need a specific management, different from younger patients.
Results: Data from analyzed studies, both gastro esophageal and pancreatic cancer, are contradictory. In some reports elderly patients don’t seem to bring greater toxicity than younger. Other trials consider that dose-adjustment to renal function is need in elderly patients, but these trials are very few. Other trials may include several biases such as accrual of “only fit” elderly patients.
Conclusions: It is very important in elderly patients with higher risk of toxicity, to distinguish the aim of cancer treatment: is it curative or palliative? Furthermore, in this type of patients the most important target is probably maintaining the quality of life especially in gastric and pancreatic cancer that often started as advanced disease. For these valuation chronological age alone is not sufficient. Another very important factor in elderly cancer patients is the geriatric assessment including not only age but also functional, social and mental status.
Export Options
About this article
Cite this article as:
Silvestro Lucrezia, Nasti Guglielmo, Ottaiano Alessandro, Montano Massimo, Casaretti Rossana, Avallone Antonio, Berretta Massimiliano, Romano Carmela, Cassata Antonio, Tafuto Salvatore and Iaffaioli Vincenzo Rosario, Gastrointestinal Non Colorectal Cancer. Do Elderly Patients Need a Specific Management?, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/18715206113136660356
DOI https://dx.doi.org/10.2174/18715206113136660356 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry Developing the Evidence Base for Cancer Chemoprevention: Use of Meta-Analysis
Current Drug Targets 7-O-aminoalkyl-2,3-dehydrosilibinins: Synthesis and in vitro Anti-cancer Efficacy
Anti-Cancer Agents in Medicinal Chemistry Population Pharmacogenomics and Personalized Medicine Research in Hungary: Achievements and Lessons Learned
Current Pharmacogenomics and Personalized Medicine The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy
Current Cancer Drug Targets Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Tumor-Induced Alterations in Lipid Metabolism
Current Medicinal Chemistry Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry Microfluidic approaches to synchrotron radiation-based Fourier transform infrared (SR-FTIR) spectral microscopy of living biosystems
Protein & Peptide Letters An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity
Current Cancer Drug Targets Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Dendritic Cells in Esophageal Adenocarcinoma: The Currently Available Information and Possibilities to use Dendritic Cells for Immunotherapeutic Approaches
Current Pharmaceutical Design Sanguinarine: A Double-Edged Sword of Anticancer and Carcinogenesis and Its Future Application Prospect
Anti-Cancer Agents in Medicinal Chemistry To Seek Shelter from the Wnt in Osteoarthritis? Wnt-Signaling as a Target for Osteoarthritis Therapy
Current Drug Targets Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Role of Nitric Oxide in Physiology and Pathology of the Gastrointestinal Tract
Mini-Reviews in Medicinal Chemistry Inflammatory and Non-Inflammatory Roles for Toll-Like Receptors in Gastrointestinal Cancer
Current Pharmaceutical Design